Clinical trials: IGA Glomerulonephritis
IgA Nephropathy
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d.
- Trial name
- APPLAUSE-IgAN (NCT04578834)
- Testing
- LNP023
- Where
- 177 sites in United States, Argentina and 33 more
- Volunteers
- 518 people
- Sponsor
- Novartis Pharmaceuticals
Primary IgA Nephropathy
A Study of Telitacicept for IgA Nephropathy (TELIGAN)
The purpose of this study is to evaluate the efficacy and safety of Telitacicept in patients with primary IgA nephropathy at risk of progressing to end-stage renal disease(ESRD), despite maximum tolerated treatment with…
- Trial name
- NCT05799287
- Testing
- Telitacicept
- Where
- 101 sites in China
- Volunteers
- 318 people
- Sponsor
- RemeGen Co., Ltd.
IgA Glomerulonephritis
Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
This study will evaluate the long-term efficacy and safety of low dose oral methylprednisolone compared to matching placebo, on a background of routine RAS inhibitor therapy, in preventing kidney events in patients with IgA…
- Trial name
- TESTING (NCT01560052)
- Testing
- methylprednisolone
- Where
- 66 sites in Australia, Canada and 4 more
- Volunteers
- 503 people
- Sponsor
- The George Institute
IgA Nephropathy
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy
IgA nephropathy (IgAN) is the most common type of glomerulonephritis worldwide. 15-40% of individuals diagnosed with IgAN, including children, will eventually progress to chronic renal insufficiency (CRI) and end stage renal…
- Trial name
- NCT00318474
- Testing
- Mycophenolate Mofetil (MMF), ACEi, FOS
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
IgA Nephropathy (IgAN), Henoch Schönlein Purpura Nephritis
To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
The goal of this open-label, randomized study is to evaluate the efficacy and safety of the personalized treatment model in which Gd-IgA1 is dynamically monitored to guide medication adjustment in progressive IgAN patients…
- Trial name
- NCT07822100
- Testing
- Gd-IgA1 monitoring
- Where
- China
- Volunteers
- 374 people
- Sponsor
- Hong Zhang
Finerenone, IgA Nephropathy
Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy
IgA nephropathy accounts for about 45 per cent of primary glomerular diseases in China and about 26 per cent of renal biopsies in patients with chronic failure.According to current guideline recommendations, there are limited…
- Conditions
- Finerenone, IgA Nephropathy, Proteinuria, Safety Issues
- Trial name
- NCT06460987
- Testing
- Finerenone, RAS inhibitor, Immune Suppressant
- Where
- China
- Volunteers
- 245 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
IgA Nephropathy
Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy
The anti-hinge region antibodies would be a relevant biomarker of IgA nephropathy. Beyond a prognostic value (which could increase the risk of Renal Absolute), the longitudinal monitoring for these antibodies could be of…
- Trial name
- NIGA-RA (NCT02526966)
- Testing
- blood sample
- Where
- 15 sites in France
- Volunteers
- 68 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
IgA Nephropathy
A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical study with an optional open label extension to evaluate the safety and efficacy of Telitacicept for Injection (RC18) in the treatment of IgA…
- Trial name
- NCT04905212
- Testing
- Telitacicept 160mg, Telitacicept 240mg
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- RemeGen Co., Ltd.
IgA Nephropathy
Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy
Evaluation of the efficacy of an immunosuppressive therapy added to a comprehensive supportive therapy to induce a clinical remission in patients at risk for progressive IgAN Investigation of differences between the treatments…
- Trial name
- STOP-IgAN (NCT00554502)
- Testing
- supportive therapy with: ACE-inhibitor / ARB / Statin, supportive and immunosuppressive therapy
- Where
- 34 sites in Germany
- Volunteers
- 148 people
- Sponsor
- RWTH Aachen University
IGA Glomerulonephritis
Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis
OBJECTIVES: I. Determine whether allelic differences associated with the fourth component of complement, type-1 complement receptor expressed on erythrocytes, and Fc receptor FcgRIII contribute to the pathogenesis of IgA…
- Trial name
- NCT00004305
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- National Center for Research Resources (NCRR)
Chronic Kidney Disease, IgA Nephropathy
Pilot Study of Velcade® in IgA Nephropathy
The primary objective of this study is to investigate the ability of Velcade® (bortezomib) to induce complete or partial remission in patients with severe IgA nephropathy.
- Trial name
- NCT01103778
- Testing
- Bortezomib (Velcade®)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- The Rogosin Institute
IgA Nephropathy
IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
The investigators are registering all biopsy-proven primary IgA nephropathy (IgAN) patients at recruited hospitals and developing a IgAN database in China.
- Trial name
- NCT03001947
- Testing
- No intervention
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Sun Yat-sen University
IgA Nephropathy
BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration
The purpose of this study is to evaluate the efficacy and safety of subcutaneous blisibimod administration in addition to standard therapy in patients with biopsy proven IgA Nephropathy with persistent proteinuria of between 1-6…
- Trial name
- NCT02062684
- Testing
- Blisibimod
- Where
- 23 sites in Czechia, Germany and 8 more
- Volunteers
- 57 people
- Sponsor
- Anthera Pharmaceuticals
IgA Nephropathy
Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
This study is an extended follow-up of the study (ClinicalTrials.gov ID: NCT01758120)-Treatment of prednisone plus cyclophosphamide may be superior to treatment of prednisone alone in patients with advanced-stage IgA nephropathy.
- Trial name
- e-TOPplus (NCT03218852)
- Testing
- prednisone and cyclophosphamide, prednisone alone
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Guangdong Provincial People's Hospital
IgA Nephropathy (IgAN)
Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN
- Trial name
- NCT06670352
- Testing
- HSK39297 50mgBID, HSK39297 100mgBID, HSK39297 200mgQD
- Where
- 2 sites in China
- Volunteers
- 87 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Immunoglobulin A Nephropathy
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.
- Trial name
- NCT06952426
- Testing
- No intervention, Other treatment, Iptacopan
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy (IgAN)
Exploring the Brain - Gut Microbiota - Kidney Interactive Damage Mechanisms Underlying Cognitive Decline in Patients With IgA Nephropathy Using Ultra-high Field Magnetic Resonance Imaging
IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. Its progression is often accompanied by cognitive decline, manifesting as multi-dimensional cognitive deficits in areas such as memory, attention…
- Trial name
- NCT07617402
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tang-Du Hospital
Lupus Nephritis, Immunoglobulin A Nephropathy
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis …
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- RUBY-3 (NCT05732402)
- Testing
- Povetacicept
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 72 people
- Sponsor
- Alpine Immune Sciences, Inc.
IgA Nephropathy
Paricalcitol for the Treatment of Immunoglobulin A Nephropathy
Immunoglobulin A (IgA) nephropathy is the common type of primary glomerulonephritis in the world. A wealth of literature suggests that vitamin D and its analogs have profound effects on immune system function and glomerular…
- Trial name
- NCT00599963
- Testing
- paricalcitol
- Where
- Hong Kong
- Sponsor
- Chinese University of Hong Kong
Minimal Change Disease (MCD), IgA Nephropathy (IgAN)
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
This is a Phase 1b/2, open-label, multi-center study evaluating the therapeutic potential and safety of the investigational drug EVER001 in adults with FSGS, MCD, or IgAN.
- Conditions
- Minimal Change Disease (MCD), IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- NCT07614477
- Testing
- EVER001
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- Everest Medicines (China) Co.,Ltd.